RxDoctor Payments Data

Jennifer Sedlak

Family · Cleveland, OHNPI 1992335566

Payments from drug & device makers

$3,401in general payments, 2019–2025

Across 54 payments — averaging $62.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$1K
  • TG Therapeutics, Inc.$584
  • E.r. Squibb & Sons, L.L.C.$545
  • Novartis$326
  • Genentech, Inc.$271
  • EMD Serono, Inc.$193
  • plus $352 from 6 others

What the payments were for

  • Consulting fees$1,01030%
  • Food & beverage$2,19164%
  • Education$2006%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,401 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$24,977
Medicare patients
143
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab84$851,167
VumerityDiroximel Fumarate77$650,816
TecfideraDimethyl Fumarate43$397,768
ZeposiaOzanimod Hydrochloride14$158,244
CopaxoneGlatiramer Acetate27$147,235
AubagioTeriflunomide13$121,560
Dalfampridine ErDalfampridine144$97,576
Glatiramer Acetate19$54,783
FingolimodFingolimod Hcl78$50,303
Teriflunomide43$27,202
GlatopaGlatiramer Acetate13$26,135
Dimethyl Fumarate35$24,224
Gabapentin483$9,811
MyrbetriqMirabegron12$7,624
Baclofen243$6,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Tecfidera$1,130$1,048,585120 claims
E.r. Squibb & Sons, L.L.C.Zeposia$545$158,24414 claims
SanofiAubagio$36$121,56013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →